<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7332877\results\search\disease\results.xml">
  <result pre="2019-nCOV. Alongside, 2019-nCOV Mpro sequence is non-homologous to human host-pathogen." exact="Complete" post="genome sequence analysis, structural and molecular docking results revealed"/>
  <result pre="forming H-bond with Remdesivir during 100â€‰ns simulations run and found" exact="stable" post="(âˆ¼99%) by RMSD and RMSF. Thus, present in silico"/>
  <result pre="table-count: page-count: word-count: Introduction At first, an unknown case of" exact="pneumonia" post="was detected in Wuhan, China, and was communicated to"/>
  <result pre="virus that causes a range of illnesses including Middle East" exact="Respiratory" post="Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). SARS,"/>
  <result pre="that causes a range of illnesses including Middle East Respiratory" exact="Syndrome" post="(MERS) and Severe Acute Respiratory Syndrome (SARS). SARS, due"/>
  <result pre="range of illnesses including Middle East Respiratory Syndrome (MERS) and" exact="Severe" post="Acute Respiratory Syndrome (SARS). SARS, due to SARS-CoV was"/>
  <result pre="of illnesses including Middle East Respiratory Syndrome (MERS) and Severe" exact="Acute" post="Respiratory Syndrome (SARS). SARS, due to SARS-CoV was initially"/>
  <result pre="illnesses including Middle East Respiratory Syndrome (MERS) and Severe Acute" exact="Respiratory" post="Syndrome (SARS). SARS, due to SARS-CoV was initially identified"/>
  <result pre="including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory" exact="Syndrome" post="(SARS). SARS, due to SARS-CoV was initially identified in"/>
  <result pre="which was caused by MERS-CoV infection. The most recent coronavirus," exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), provisionally called 2019"/>
  <result pre="was caused by MERS-CoV infection. The most recent coronavirus, Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), provisionally called 2019 novel"/>
  <result pre="caused by MERS-CoV infection. The most recent coronavirus, Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2), provisionally called 2019 novel coronavirus"/>
  <result pre="by MERS-CoV infection. The most recent coronavirus, Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2), provisionally called 2019 novel coronavirus (2019-nCOV),"/>
  <result pre="and newest member of the Coronavirus which reports to be" exact="infectious" post="to humans (Zhu etÂ al., 2020). Currently, 4,647,961 confirmed"/>
  <result pre="(Zhu etÂ al., 2020). Currently, 4,647,961 confirmed cases and 308,985" exact="total" post="deaths due to 2019-nCOV had been reported worldwide as"/>
  <result pre="of Health and Family Welfare have reported 85,940 and 30,153" exact="total" post="confirmed cases and deaths respectively (www.mohfw.gov.in). The contagious virus"/>
  <result pre="(www.mohfw.gov.in). The contagious virus 2019-nCOV can spread primarily through the" exact="viral" post="droplets of saliva and discharges from the nose of"/>
  <result pre="also touching contaminated surfaces (Pant etÂ al., 2020). The typical" exact="viral infection" post="symptoms of 2019-nCoV are dry cough, running nose, fever,"/>
  <result pre="touching contaminated surfaces (Pant etÂ al., 2020). The typical viral" exact="infection" post="symptoms of 2019-nCoV are dry cough, running nose, fever,"/>
  <result pre="cases. Some cases reported severe conditions such as pneumonia, severe" exact="acute" post="respiratory distress syndrome, kidney failure with fatal consequences (Elfiky,"/>
  <result pre="Some cases reported severe conditions such as pneumonia, severe acute" exact="respiratory" post="distress syndrome, kidney failure with fatal consequences (Elfiky, 2020)."/>
  <result pre="severe conditions such as pneumonia, severe acute respiratory distress syndrome," exact="kidney failure" post="with fatal consequences (Elfiky, 2020). However, as of now,"/>
  <result pre="several researchers have recognized that to investigate the routes of" exact="viral" post="spread among humans, the site of activation must be"/>
  <result pre="with 2019-nCOV were similar to influenza, and both viruses cause" exact="respiratory" post="issues. Influenza is a communicable disease caused by the"/>
  <result pre="influenza, and both viruses cause respiratory issues. Influenza is a" exact="communicable disease" post="caused by the influenza virus. This RNA virus contains"/>
  <result pre="and both viruses cause respiratory issues. Influenza is a communicable" exact="disease" post="caused by the influenza virus. This RNA virus contains"/>
  <result pre="(bird flu), H7N7 (unusual zoonotic potential), and H7N2 (low pathogenicity" exact="avian influenza" post="virus) (Hay etÂ al., 2001). The study on viral"/>
  <result pre="avian influenza virus) (Hay etÂ al., 2001). The study on" exact="viral" post="composition revealed that the Hemagglutinin-Esterase (HE) glycoprotein gene is"/>
  <result pre="critical components of the 2019-nCoV life cycle. The lifecycle includes" exact="viral" post="entry into the host cell, viral replication, and viral"/>
  <result pre="cycle. The lifecycle includes viral entry into the host cell," exact="viral" post="replication, and viral RNA synthesis (Boopathi etÂ al., 2020)."/>
  <result pre="includes viral entry into the host cell, viral replication, and" exact="viral" post="RNA synthesis (Boopathi etÂ al., 2020). The previous research"/>
  <result pre="role in processing the polyproteins that are translated from the" exact="viral" post="RNA (Anand etÂ al., 2003; Hilgenfeld, 2014; Ton etÂ"/>
  <result pre="analog which can cause pre-mature RNA termination of the nascent" exact="viral" post="RNA. A double-blinded, placebo-controlled study (Remdesivir 200â€‰mg intravenously administered"/>
  <result pre="of the cellular receptors of SARS-CoV (Vincent etÂ al., 2005)." exact="Multiple" post="types of studies (double blind, Phase 3, randomized, open-label"/>
  <result pre="Favipiravir an antiviral drug, known to effectively inhibit the 2019-nCOV" exact="infection" post="in Vero E6 cells. An open-label non-randomized control study"/>
  <result pre="study was conducted in the National Clinical Research Centre for" exact="Infectious" post="Diseases Shenzhen, China, to assess the effectiveness of Favipiravir"/>
  <result pre="was conducted in the National Clinical Research Centre for Infectious" exact="Diseases" post="Shenzhen, China, to assess the effectiveness of Favipiravir in"/>
  <result pre="showed significant assistance in terms of health progress by faster" exact="viral" post="clearance and with further research, this can be considered"/>
  <result pre="be considered as a standard treatment to combat the SARS-CoV-2" exact="infection" post="(Cai etÂ al., 2020). Further, a randomized controlled trial"/>
  <result pre="of three drugs, i.e. Ribavirin, Penciclovir, and Favipiravir, shown to" exact="lower" post="the viral infection. Nafamostat, a potent inhibitor of MERS-CoV,"/>
  <result pre="drugs, i.e. Ribavirin, Penciclovir, and Favipiravir, shown to lower the" exact="viral infection." post="Nafamostat, a potent inhibitor of MERS-CoV, was inhibitive against"/>
  <result pre="a potent inhibitor of MERS-CoV, was inhibitive against the 2019-nCoV" exact="infection" post="since it prevents membrane fusion. Nitazoxanide, an anti-protozoal agent"/>
  <result pre="Remdesivir and Chloroquine were also found to be potently blocking" exact="virus infection" post="at low-micromolar concentration. Other antiviral drugs viz., Oseltamivir, and"/>
  <result pre="and Chloroquine were also found to be potently blocking virus" exact="infection" post="at low-micromolar concentration. Other antiviral drugs viz., Oseltamivir, and"/>
  <result pre="under interventional (Phase 3, clinical) trial to treat the 2019-nCoV" exact="Pneumonia" post="in China and Thailand (https://clinicaltrials.gov/ct2/show/NCT04261270; https://clinicaltrials.gov/ct2/show/NCT04303299). Clinical trials for"/>
  <result pre="there is a need to identify the drug which targets" exact="viral" post="replication especially on the Mpro enzyme of 2019-nCoV. The"/>
  <result pre="San Diego, USA). Sequence analysis According to the Centers for" exact="Disease" post="Control and Prevention: CDC (https://www.cdc.gov/coronavirus/types.html) and World Health Organization:"/>
  <result pre="of 1960s (Killerby etÂ al., 2018) around the globe and" exact="primary" post="sub-groupings of coronaviruses are known as alpha, beta, gamma,"/>
  <result pre="coronaviruses are known as alpha, beta, gamma, and delta. Commonly" exact="infective" post="human coronaviruses are 229E (alpha), NL63 (alpha), OC43 (beta),"/>
  <result pre="sequence comparison is essential to analyses the evolutionary relationship of" exact="viral" post="genomes. With the swift growth of sequence and structure"/>
  <result pre="AUM60013 (6) SARS-CoV: AAY88865 and (7) 2019-nCoV: YP_009725295 from NCBI" exact="Viral" post="genome database to discover the evolutionary relationship by phylogenetic"/>
  <result pre="antiviral agents are in use for the treatment of 2019-nCoV" exact="viral infection." post="However, numerous examples exist in which the utilization of"/>
  <result pre="of either option or a combination therapeutic approach. As 2019-nCoV" exact="infections" post="have risen, the focus on encoded proteases to discover"/>
  <result pre="medications are in progress. Recent molecular studies have demonstrated that" exact="viral" post="proteaseâ€™s existence pattern depends upon numerous infections by affecting"/>
  <result pre="have demonstrated that viral proteaseâ€™s existence pattern depends upon numerous" exact="infections" post="by affecting the cleavage/catalyzing process of viral polyprotein antecedents"/>
  <result pre="depends upon numerous infections by affecting the cleavage/catalyzing process of" exact="viral" post="polyprotein antecedents (which are high molecular weight)/essential proteins important"/>
  <result pre="inhibitors are utilized principally for the treatment of Herpesvirus, Human" exact="Immunodeficiency" post="Virus (HIV), Respiratory Syncytial Infection and flu A viruses,"/>
  <result pre="principally for the treatment of Herpesvirus, Human Immunodeficiency Virus (HIV)," exact="Respiratory" post="Syncytial Infection and flu A viruses, and can also"/>
  <result pre="the treatment of Herpesvirus, Human Immunodeficiency Virus (HIV), Respiratory Syncytial" exact="Infection" post="and flu A viruses, and can also be used"/>
  <result pre="identify novel compounds of therapeutic interest for the emerging pandemic" exact="infectious" post="outbreaks by predicting the inhibitor-receptor interactions. Even though it"/>
  <result pre="al., 2018; Munikumar etÂ al., 2019; Pradhan etÂ al., 2014)." exact="Protein" post="structure preprocessing and optimization Three-dimensional structure of 2019-nCoV Mpro"/>
  <result pre="(SPC) of the HOH molecule model was accounted. Alongside, orthorhombic" exact="periodic" post="boundary box (X, Y, and Z-axis) conditions were set"/>
  <result pre="and Stage 9: Production time minimization at 100â€‰ns with the" exact="periodic" post="boundary conditions in the NPT ensemble using OPLS 2005"/>
  <result pre="(RMSF), radius of gyration (rGyr), Solvent-Accessible Surface Area (SASA), and" exact="total" post="intramolecular H-bonds contributing to the structural stability. The SQA"/>
  <result pre="time for the given temperature, pressure, and volume of the" exact="total" post="simulation box. Results and discussion Phylogenetic analysis Multiple sequence"/>
  <result pre="of the total simulation box. Results and discussion Phylogenetic analysis" exact="Multiple" post="sequence alignment of the retrieved Mpro sequences was performed,"/>
  <result pre="internal node in the tree. For interim datasets preparation, a" exact="total" post="of 7444 pair-wise positions were constituted with seven Mpro"/>
  <result pre="analysis is performed with 500â€‰Mpro protein sequence from the NCBI" exact="viral" post="genome database (till 4th May 2020) (Figure 1B). The"/>
  <result pre="2019-nCoV is an enveloped positive-sense single-strand RNA virus, infecting primarily" exact="respiratory" post="system. It also infects the gastrointestinal epithelial cells, macrophages,"/>
  <result pre="virus, infecting primarily respiratory system. It also infects the gastrointestinal" exact="epithelial" post="cells, macrophages, and other cell types, thereby triggering the"/>
  <result pre="epithelial cells, macrophages, and other cell types, thereby triggering the" exact="systemic" post="changes and damage to many vital organs for instance"/>
  <result pre="kidney and adrenal gland. Anti-2019-nCoV therapeutics could target several major" exact="viral" post="pathogeneses, such as virus-cell interactions, virus entry, intracellular viral"/>
  <result pre="major viral pathogeneses, such as virus-cell interactions, virus entry, intracellular" exact="viral" post="replication, and virus assembly and exit (Lu, 2020; Medhi"/>
  <result pre="Sequence alignment of 2019-nCoV Mpro with SARS-CoV Mpro. (A) The" exact="secondary" post="structure of peptidase in the alignment were assigned using"/>
  <result pre="The docked and native complexes are depicted the average of" exact="total" post="energy (âˆ’132446.36 and âˆ’99501.23â€‰kcal/mol), potential energy (âˆ’162734.98 and âˆ’121628.90â€‰kcal/mol)"/>
  <result pre="potential energy (âˆ’162734.98 and âˆ’121628.90â€‰kcal/mol) of the system was relatively" exact="stable" post="with the average temperature (298.65â€‰kelvin), pressure (1.88â€‰bar), and volume"/>
  <result pre="RMSD score with native Mpro and docked complex was not" exact="stable" post="significantly throughout the MD simulation run (Figure 6A). The"/>
  <result pre="of 0.88â€‰Ã…, 1.39â€‰Ã…, 0.94â€‰Ã… and 1.44â€‰Ã… respectively, which denotes the" exact="lower" post="atomic fluctuations in binding residues indicating smaller conformational changes"/>
  <result pre="in binding residues indicating smaller conformational changes (Figure 6B). The" exact="total" post="energy, potential energy, RMSD and RMSF analysis revealed that"/>
  <result pre="that the 2019-nCoV Mpro â€&quot; Remdesivir docking complex was highly" exact="stable" post="during the entire 100â€‰ns MD simulations. Figure 6. Molecular"/>
  <result pre="structure of Mpro residues Gly143, Cys-145 were observed to remain" exact="stable" post="in all the trajectories during MD simulations run (Figure"/>
  <result pre="additionally, Leu141 was formed H-bond with Mpro of 2019-nCoV remained" exact="stable" post="throughout the period of 100â€‰ns molecular dynamics simulations. Figure"/>
  <result pre="towards native and docked depicts 23.66â€‰Ã… and 22.77â€‰Ã…, respectively displayed" exact="stable" post="over time, suggesting that both complexes have reached a"/>
  <result pre="anti-viral activity against RNA viruses and also are selective for" exact="viral" post="polymerases along with low susceptibility to cause any human"/>
  <result pre="and also are selective for viral polymerases along with low" exact="susceptibility to" post="cause any human toxicity (Agostini etÂ al., 2018; Sheahan"/>
  <result pre="has a good docking score with strong binding affinity and" exact="stable" post="confirmations with the crucial residues Cys145, and His164 of"/>
  <result pre="multiple-dose phase intravenous between 3â€‰mg and 225â€‰mg. The risk for" exact="central nervous system," post="respiratory, or cardiovascular effects was considered low at projected"/>
  <result pre="and 225â€‰mg. The risk for central nervous system, respiratory, or" exact="cardiovascular" post="effects was considered low at projected therapeutic exposures and"/>
  <result pre="and SARS CoV) and paramyxoviruses (Nipah and Hendra) discerning for" exact="viral" post="polymerases. Thus, the present in silico and ongoing clinical"/>
  <result pre="is a potent inhibitor against 2019-nCoV. Conclusion The novel human" exact="respiratory" post="coronavirus initially called as 2019 â€&quot; Novel Coronavirus (2019-nCOV)"/>
  <result pre="called as 2019 â€&quot; Novel Coronavirus (2019-nCOV) and now called" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has emphasized the"/>
  <result pre="as 2019 â€&quot; Novel Coronavirus (2019-nCOV) and now called Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has emphasized the insurgency"/>
  <result pre="2019 â€&quot; Novel Coronavirus (2019-nCOV) and now called Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) has emphasized the insurgency for"/>
  <result pre="â€&quot; Novel Coronavirus (2019-nCOV) and now called Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) has emphasized the insurgency for therapeutic"/>
  <result pre="alternatives to alleviate and stop a novel evolving epidemic of" exact="infectious" post="zoonotic diseases. Till now no therapeutic vaccine and drugs"/>
  <result pre="L., ClarkeM. O., BaricR. S., &amp;amp; DenisonM. R. (2018). Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease. mBio, 9(2), 1â€&quot;15. 10.1128/mBio.00221-18"/>
  <result pre="Kumar PutchaU., &amp;amp; GourineniS. R. (2018). Tamarind fruit extract ameliorates" exact="fluoride toxicity" post="by upregulating carbonic anhydrase II: A mechanistic study. Fluoride,"/>
  <result pre="HorzinekM. C., &amp;amp; SpaanW. J. M. (1988). Sequence of mouse" exact="hepatitis" post="virus A59 mRNA 2: Indications for RNA recombination between"/>
  <result pre="Discovery of potential lumazine synthase antagonists for pathogens involved in" exact="bacterial" post="meningitis: In silico study. Informatics in Medicine Unlocked, 15,"/>
  <result pre="KalantriS. (2020). Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet" exact="Infectious" post="Diseases. [In press]. 10.1016/S1473-3099(20)30313-3 SheahanT. P., SimsA. C., LeistS."/>
  <result pre="Docking studies towards exploring antiviral compounds against envelope protein of" exact="yellow fever" post="virus. Interdisciplinary Sciences, Computational Life Sciences, 3(1), 64â€&quot;77. 10.1007/s12539-011-0064-y"/>
  <result pre="T. (2005). Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virology Journal, 2(1), 6910.1186/1743-422X-2-6916115318 WangM., CaoR., ZhangL.,"/>
  <result pre="M., PanC., &amp;amp; JiangS. (2020). Measures for diagnosing and treating" exact="infections" post="by a novel coronavirus responsible for a pneumonia outbreak"/>
  <result pre="and treating infections by a novel coronavirus responsible for a" exact="pneumonia" post="outbreak originating in Wuhan, China. Microbes and Infection, 22(2),"/>
  <result pre="F., &amp;amp; TanW. (2020). A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. New England Journal of Medicine, 382(8),"/>
  <result pre="(CoV) Coronavirus (HE) Hemagglutinin-Esterase (Mpro) Main protease (MERS) Middle East" exact="Respiratory" post="Syndrome (MD) Molecular Dynamics (NPT) Number of atoms, Pressure,"/>
  <result pre="Coronavirus (HE) Hemagglutinin-Esterase (Mpro) Main protease (MERS) Middle East Respiratory" exact="Syndrome" post="(MD) Molecular Dynamics (NPT) Number of atoms, Pressure, Temperature"/>
  <result pre="(MD) Molecular Dynamics (NPT) Number of atoms, Pressure, Temperature (PDB)" exact="Protein" post="Data Bank (rGyr) Radius of Gyration (RdRp) RNAâ€�dependent RNA"/>
  <result pre="of Gyration (RdRp) RNAâ€�dependent RNA polymerase (RMSD) Root Mean Square" exact="Deviation" post="(RMSF) Root Mean Square Fluctuation (SARS) Severe Acute Respiratory"/>
  <result pre="Root Mean Square Deviation (RMSF) Root Mean Square Fluctuation (SARS)" exact="Severe" post="Acute Respiratory Syndrome (SARS-CoV-2) Severe Acute Respiratory Syndrome Coronavirus"/>
  <result pre="Mean Square Deviation (RMSF) Root Mean Square Fluctuation (SARS) Severe" exact="Acute" post="Respiratory Syndrome (SARS-CoV-2) Severe Acute Respiratory Syndrome Coronavirus 2"/>
  <result pre="Square Deviation (RMSF) Root Mean Square Fluctuation (SARS) Severe Acute" exact="Respiratory" post="Syndrome (SARS-CoV-2) Severe Acute Respiratory Syndrome Coronavirus 2 (SEA)"/>
  <result pre="Deviation (RMSF) Root Mean Square Fluctuation (SARS) Severe Acute Respiratory" exact="Syndrome" post="(SARS-CoV-2) Severe Acute Respiratory Syndrome Coronavirus 2 (SEA) Simulation"/>
  <result pre="Root Mean Square Fluctuation (SARS) Severe Acute Respiratory Syndrome (SARS-CoV-2)" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SEA) Simulation Event Analysis"/>
  <result pre="Mean Square Fluctuation (SARS) Severe Acute Respiratory Syndrome (SARS-CoV-2) Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SEA) Simulation Event Analysis (SQA)"/>
  <result pre="Square Fluctuation (SARS) Severe Acute Respiratory Syndrome (SARS-CoV-2) Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SEA) Simulation Event Analysis (SQA) Simulation"/>
  <result pre="Fluctuation (SARS) Severe Acute Respiratory Syndrome (SARS-CoV-2) Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SEA) Simulation Event Analysis (SQA) Simulation Quality"/>
 </snippets>
</snippetsTree>
